Davicević Zaklina, Tavciovski Dragan, Matunović Radomir
Klinika za kardiologiju, Vojnomedicinska akademija, Beograd.
Med Pregl. 2010 Jan-Feb;63(1-2):82-5. doi: 10.2298/mpns1002082d.
Aortic stenosis is the most frequent valvular heart disease in western world and its incidence continues to rise. Aortic sclerosis is the first characteristic lesion of the cusps, which is today considered a process similar to atherosclerosis. The progression of the disease is an active process leading to forming of bone matrix and heavily calcified stiff cusps by inflammatory cells and osteopontin. Aortic stenosis is a chronic, progressive disease which can remain asymptomatic for a long time even in the presence of severe aortic stenosis. MEDICAL TREATMENT FOR AORTIC STENOSIS: The need for alternative to aortic valve surgery is highlighted by increasing longevity of the population and new therapeutic strategies to limit disease progression are needed to delay or potentially avoid, the need for valve surgery. Currently, there are no established disease modifying treatments in regard to the progression of aortic stenosis. The first results about influence of angiotensin-converting enzyme inhibitors and statins on aortic sclerosis and stenosis progression are promising. Statins are likely to reduce cardiovascular events rather than disease progression, but may be potentially a valuable preventive treatment in these patients. The prejudice against the use of angiotensin-converting enzyme inhibitors by patients with aortic stenosis is changing. The cautious use of angiotensin-converting enzyme inhibition by patients with concomitant hypertension, coronary artery disease, and heart failure seems appropriate. Definite evidence from large clinical trials is awaited.
主动脉瓣狭窄是西方世界最常见的瓣膜性心脏病,其发病率持续上升。主动脉瓣硬化是瓣叶的首个特征性病变,如今被认为是一个与动脉粥样硬化相似的过程。疾病进展是一个活跃过程,炎症细胞和骨桥蛋白会导致骨基质形成以及瓣叶严重钙化僵硬。主动脉瓣狭窄是一种慢性进行性疾病,即使存在严重的主动脉瓣狭窄,很长一段时间内也可能无症状。主动脉瓣狭窄的药物治疗:随着人口寿命的延长,对主动脉瓣手术替代方案的需求凸显出来,需要新的治疗策略来限制疾病进展,以延迟或可能避免瓣膜手术的需求。目前,关于主动脉瓣狭窄的进展,尚无既定的疾病改善治疗方法。关于血管紧张素转换酶抑制剂和他汀类药物对主动脉瓣硬化和狭窄进展影响的初步结果很有前景。他汀类药物可能会减少心血管事件而非疾病进展,但在这些患者中可能是一种有价值的预防性治疗方法。主动脉瓣狭窄患者对使用血管紧张素转换酶抑制剂的偏见正在改变。对于合并高血压、冠状动脉疾病和心力衰竭的患者,谨慎使用血管紧张素转换酶抑制剂似乎是合适的。尚需大型临床试验的确切证据。